Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ViroPharma Inc. (“ViroPharma” or the “Company”) (NasdaqGS:VPHM) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Shire (NasdaqGS: SHPG) in a cash deal valued at approximately $4.2 billion. Under the terms of the proposed transaction, ViroPharma’s stockholders will receive $50.00 for each share of ViroPharma common stock they own. Request more information now by clicking here: www.faruqilaw.com/VPHM.There is no cost or obligation to you. The investigation focuses on whether ViroPharma’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of ViroPharma’s shareholders. Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw. If you own common stock in ViroPharma and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/VPHM or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.